Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clascoterone - Cosmo Pharmaceuticals

Drug Profile

Clascoterone - Cosmo Pharmaceuticals

Alternative Names: Breezula; CB-03-01; Clascoterone - Cassiopea; Cortexolone 17alpha-propionate; WINLEVI; Winlevi

Latest Information Update: 17 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cassiopea; Cosmo Pharmaceuticals; Sun Pharmaceutical Industries
  • Class Antiacnes; Esters; Pregnenediones; Propionates; Skin disorder therapies; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acne vulgaris
  • Phase III Alopecia

Most Recent Events

  • 12 Jun 2024 Zhejiang Sunshine Mandi Pharmaceutical (a subsidiary of 3SBio) plans a phase I pharmacokinetics trial in Healthy adult volunteers (Topical) in July 2024 (NCT06454708)
  • 08 Mar 2024 Registered for Acne vulgaris (In adolescents, In adults) in Australia (Topical)
  • 27 Sep 2023 Clascoterone licensed to Glenmark Pharmaceuticals Ltd. in Bulgaria, Czech Republic, Denmark, Finland, France, Hungary, Iceland, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain and Sweden, South Africa and United Kingdom
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top